Skip Navigation LinksHome > Current Issue > Induction of Cytomegalovirus-Specific T Cell Responses in He...
Transplantation:
doi: 10.1097/TP.0000000000000272
Clinical Science

Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA–Transfected Dendritic Cells

Van Craenenbroeck, Amaryllis H.1,2; Smits, Evelien L.J.3,4; Anguille, Sébastien3,4; Van de Velde, Ann5; Stein, Barbara4; Braeckman, Tessa6; Van Camp, Kirsten3; Nijs, Griet4; Ieven, Margareta7; Goossens, Herman7; Berneman, Zwi N.3,4,5; Van Tendeloo, Viggo F.I.3; Verpooten, Gert A.1,2; Van Damme, Pierre6; Cools, Nathalie3

Open Access
Supplemental Author Material
Collapse Box

Abstract

Background: Infection with human cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant (HSCT) recipients.

Methods: The present study explored the safety, feasibility, and immunogenicity of CMV pp65 messenger RNA–loaded autologous monocyte-derived dendritic cells (DC) as a cellular vaccine for active immunization in healthy volunteers and allogeneic HSCT recipients. Four CMV-seronegative healthy volunteers and three allogeneic HSCT recipients were included in the study. Four clinical-grade autologous monocyte-derived DC vaccines were prepared after a single leukapheresis procedure and administered intradermally at a weekly interval.

Results: De novo induction of CMV-specific T-cell responses was detected in three of four healthy volunteers without serious adverse events. Of the HSCT recipients, none developed CMV disease and one of two patients displayed a remarkable threefold increase in CMV pp65-specific T cells on completion of the DC vaccination trial.

Conclusion: In conclusion, our DC vaccination strategy induced or expanded a CMV-specific cellular response in four of six efficacy-evaluable study subjects, providing a base for its further exploration in larger cohorts.

© 2015 by Lippincott Williams & Wilkins

 

 

 

Login